Roquefort Therapeutics (LSE:ROQ) Change In Payables And Accrued Expense : £0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Change In Payables And Accrued Expense?

Roquefort Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was £0.00 Mil. It means Roquefort Therapeutics's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Roquefort Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was £0.00 Mil. It means Roquefort Therapeutics's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Roquefort Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Roquefort Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Change In Payables And Accrued Expense Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	-	-	-	-	-

Roquefort Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Roquefort Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines